title: Comparison of two different treatment protocols in Helicobacter pylori eradication.
abstract: BACKGROUND
  The prevalence of Helicobacter pylori (H pylori) in Turkey is high and eradication rates are low. As a result, alternative treatment strategies are required.
  
  
  OBJECTIVE
  To evaluate the status of H pylori eradication in Turkey by comparing the results of this study to other studies reported in the literature.
  
  
  METHODS
  Two hundred and eighty-two patients diagnosed with H pylori were included in this study. Patients were randomized into two groups. The first group consisted of 138 patients receiving 30 mg lansoprazole bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid for 14 days. The second group consisted of 144 patients who received lansoprazole 30 mg bid and amoxicillin 1 g bid for seven days, followed by metronidazole 500 mg bid, tetracycline 500 mg qid, and lansoprazole 30 mg bid for an additional seven days.
  
  
  RESULTS
  H pylori eradication rates in the first group were 53.6% according to intention-to-treat analysis, and 52.5% according to per protocol analysis. In the second group, eradication rates were 72.2% per intention-to-treat analysis and 77.6% as per protocol analysis. H pylori eradication rates in the second group were significantly higher than the first group (P=0.001, P<0.05), whereas the incidence of adverse events in the second group was significantly lower (P=0.048, P<0.05).
  
  
  CONCLUSIONS
  This study found a significant difference in eradication rates between the traditional triple therapy and modified sequential therapy groups. As a result, modified sequential therapy shows promise as an alternative treatment.
authors.affiliation: Department of Gastroenterology, Sivas Numune Hospital, and Department of Gastroenterology, Cumhuriyet University, School of Medicine, Sivas, Turkey. nadirislay@yahoo.com.tr
authors.forename: Isilay
authors.initials: I
authors.lastname: Nadir
authors.forename: Ozlem
authors.initials: O
authors.lastname: Yonem
authors.forename: Yasemin
authors.initials: Y
authors.lastname: Ozin
authors.forename: Zeki Mesut Yalin
authors.initials: ZM
authors.lastname: Kilic
authors.forename: Orhan
authors.initials: O
authors.lastname: Sezgin
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017291:Clarithromycin / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000453:epidemiology; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage / Q000627:therapeutic use*; D013752:Tetracycline / Q000008:administration & dosage / Q000627:therapeutic use*; D014421:Turkey / Q000453:epidemiology
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D064747:Lansoprazole; D008795:Metronidazole; D000658:Amoxicillin; D013752:Tetracycline; D017291:Clarithromycin